Johnson & Johnson Announces Single-Shot COVID-19 Vaccine
Breaking News

AstraZeneca COVID-19 Vaccine Outweighs The Risks Says Health Canada

Reading Time: 2 minutes

AstraZeneca has been a rise in blood clotting among many recipients of the vaccine

TDS News – Astrazenca was one of the early vaccines to be approved by the United States and Canada for emergency authorization of use. Up until a few weeks ago, there were little known side effects and was viewed as the preferred vaccine based on cost and shelf life. However in recent days, there has been multiple reports of blood clotting in recipients causing multiple countries to temporarily pause inoculation.

Upon further review of the vaccine by the World Health Organization, they have concluded the vaccine is safe and benefits vastly outweighs its side affects. In Canada, the vaccine is now only being offered to seniors over the age of 65. This comes on the heals of the Biden administrations announcement to send 1.5 million doses to Canada.

Health Canada communicated on March 11, 2021 that it was assessing these events, in collaboration with international regulatory partners, particularly the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Today, both the EMA and the MHRA communicated that the benefits of the use of the AstraZeneca vaccine continue to outweigh any risks.

Health Canada has assessed the available data on the reported events and has determined that the AstraZeneca vaccine has not been associated with an increase in the overall risk of blood clots. There have been very rare reports in Europe of blood clots associated with low levels of blood platelets (thrombocytopenia). Blood clots, sometimes fatal, can also be due to COVID-19. Health Canada will continue to work with international regulators and review data and evidence as it becomes available, including as it pertains to these rare events. The Department is also working with AstraZeneca to ensure that healthcare professionals and Canadians have the safety information they need.

To date in Canada, there has been one report of a stroke that occurred in an individual following vaccination with COVISHIELD (the version of the AstraZeneca vaccine currently being distributed in Canada). This case has been assessed by Health Canada and determined not to be related to the vaccine.

While minor and temporary adverse events, such as headache, fever, fatigue, or pain at the injection site, are common after all vaccinations, people should seek medical attention if they experience any new or worsening symptoms. Canadians are also encouraged to report any adverse events after immunization to their healthcare professionals.

As the vaccine roll out continues in Canada, Health Canada will continue to monitor the use of all COVID-19 vaccines closely. Health Canada will examine and assess any new safety concerns, and should a safety signal be confirmed, the Department will take appropriate action.

On February 26, 2021, Health Canada authorized the AstraZeneca COVID-19 vaccine and the Serum Institute of India’s (SII) version of the AstraZeneca vaccine, sponsored in Canada by Verity Pharmaceuticals Inc. To date, only the SII version of the AstraZeneca vaccine has been received and used in Canada.

More great reading